EA201890436A1 - Жидкая полимерная система доставки для длительного введения лекарственных средств - Google Patents

Жидкая полимерная система доставки для длительного введения лекарственных средств

Info

Publication number
EA201890436A1
EA201890436A1 EA201890436A EA201890436A EA201890436A1 EA 201890436 A1 EA201890436 A1 EA 201890436A1 EA 201890436 A EA201890436 A EA 201890436A EA 201890436 A EA201890436 A EA 201890436A EA 201890436 A1 EA201890436 A1 EA 201890436A1
Authority
EA
Eurasian Patent Office
Prior art keywords
long
medicines
liquid polymer
shipping system
term introduction
Prior art date
Application number
EA201890436A
Other languages
English (en)
Other versions
EA036951B1 (ru
Inventor
Джон Милтон Даунинг
Випин Саксена
Джон Миддлтон
Original Assignee
Толмар Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Толмар Интернэшнл Лимитед filed Critical Толмар Интернэшнл Лимитед
Publication of EA201890436A1 publication Critical patent/EA201890436A1/ru
Publication of EA036951B1 publication Critical patent/EA036951B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Жидкие полимерные фармацевтические композиции с биоразлагаемым жидким полиэфиром, который имеет карбоксильную концевую группу, биосовместимым растворителем и активным фармацевтическим средством применимы для введения в организм для обеспечения длительного времени высвобождения лекарственного средства.
EA201890436A 2015-08-03 2016-08-03 Жидкая полимерная система доставки для длительного введения лекарственных средств EA036951B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
EA201890436A1 true EA201890436A1 (ru) 2018-09-28
EA036951B1 EA036951B1 (ru) 2021-01-19

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890436A EA036951B1 (ru) 2015-08-03 2016-08-03 Жидкая полимерная система доставки для длительного введения лекарственных средств

Country Status (20)

Country Link
US (3) US10786515B2 (ru)
EP (2) EP3331495B1 (ru)
JP (1) JP6949820B2 (ru)
KR (1) KR20180030413A (ru)
CN (1) CN107920988B (ru)
AU (1) AU2016302252B2 (ru)
BR (1) BR112018002414B1 (ru)
CA (1) CA2994704A1 (ru)
DK (1) DK3331495T3 (ru)
EA (1) EA036951B1 (ru)
ES (1) ES2836805T3 (ru)
HK (1) HK1255638A1 (ru)
HR (1) HRP20201991T1 (ru)
HU (1) HUE052832T2 (ru)
IL (1) IL257221B (ru)
MX (1) MX2018001499A (ru)
PT (1) PT3331495T (ru)
TW (1) TWI718168B (ru)
WO (1) WO2017024027A1 (ru)
ZA (1) ZA201800591B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101728868B1 (ko) 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
CA2994704A1 (en) 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
AR116501A1 (es) 2018-09-25 2021-05-12 Tolmar Int Ltd Sistema de suministro de polímero líquido para administración extendida de drogas
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
EP4037660B1 (en) 2019-09-30 2023-11-22 Tolmar International Limited Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CA3197170A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2590696A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20100216948A1 (en) * 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
KR20130100345A (ko) * 2010-11-04 2013-09-10 신닛테츠 수미킨 가가쿠 가부시키가이샤 하드코트층 부착 폴리카보네이트
EP2717914B1 (en) * 2011-06-10 2019-10-30 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
EP2768544A4 (en) * 2011-10-17 2015-06-24 Poly Med Inc ABSORBABLE IN SITU-MELAGING SYSTEM, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
CA2994704A1 (en) 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs

Also Published As

Publication number Publication date
EP3331495A1 (en) 2018-06-13
US10786515B2 (en) 2020-09-29
BR112018002414A2 (pt) 2018-09-18
ES2836805T3 (es) 2021-06-28
US20180214459A1 (en) 2018-08-02
KR20180030413A (ko) 2018-03-22
MX2018001499A (es) 2018-08-01
CA2994704A1 (en) 2017-02-09
ZA201800591B (en) 2021-07-28
AU2016302252A1 (en) 2018-02-22
HRP20201991T1 (hr) 2021-02-05
CN107920988A (zh) 2018-04-17
WO2017024027A1 (en) 2017-02-09
BR112018002414B1 (pt) 2023-11-21
US20240066039A1 (en) 2024-02-29
JP6949820B2 (ja) 2021-10-13
IL257221A (en) 2018-03-29
US11779589B2 (en) 2023-10-10
EP3331495B1 (en) 2020-11-04
TW201717960A (zh) 2017-06-01
HK1255638A1 (zh) 2019-08-23
TWI718168B (zh) 2021-02-11
EP3804698A1 (en) 2021-04-14
IL257221B (en) 2022-01-01
CN107920988B (zh) 2021-08-17
DK3331495T3 (da) 2020-12-14
JP2018522906A (ja) 2018-08-16
PT3331495T (pt) 2020-12-07
HUE052832T2 (hu) 2021-05-28
US20210060036A1 (en) 2021-03-04
EP3804698B1 (en) 2024-01-31
EA036951B1 (ru) 2021-01-19
AU2016302252B2 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
MY191574A (en) Pharmaceutical compositions comprising meloxicam
NZ746573A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CU24520B1 (es) Nanocomplejo micelar de conjugados de polímero-flavonoide para la administración de fármacos antitumorales
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
EP3177270A4 (en) Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
AR097973A1 (es) FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO
PE20160534A1 (es) Sistema de administracion intrauterina
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
CL2016000944A1 (es) Nueva formulación de ganadotropinas
EP3275431A4 (en) System for homogenization of drug in biodegradable polymer: smart polymeric system
EA201390646A1 (ru) Фармацевтические композиции
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel